---

Transaction Summary

• Robust pipeline with development stage candidates across multiple indications
• Closed $70M private financing in October 2015 to continue developing pipeline
• Results from Phase II trials in 2016 - 2017 a key milestone that could trigger an acquisition of the company
• Strong interest from strategics could result in sale of development programs for significant up-front payment plus milestones

• Ballerup, Denmark


• Contact:
  Göran Ando
  
• www.symphogen.com
• Acquisition
• Acquired by: Servier

Related News

• Symphogen Issued United States Patent Covering Symplex™ Technology for Antibody Discovery
• Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology
• Symphogen and Open Monoclonal Technology Announce Collaboration
• Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGa